A Case of Therapy-related Myeloid Neoplasm after Successful Treatment of Acute Promyelocytic Leukemia

2011 ◽  
Vol 1 (4) ◽  
pp. 227 ◽  
Author(s):  
Aerin Kwon ◽  
Ji-Young Park ◽  
Jung Hye Kwon ◽  
Hun Ho Song ◽  
Kyu Sung Shin ◽  
...  
Keyword(s):  
Acute Promyelocytic Leukemia ◽  
Successful Treatment ◽  
Promyelocytic Leukemia ◽  
Myeloid Neoplasm

Myeloid neoplasm with eosinophilia and PCM1-JAK2 associated with acute promyelocytic leukemia with PML-RARA

2019 ◽  
Vol 60 (9) ◽  
pp. 2299-2303
Author(s):  
Sajad Salehi ◽  
John M. Astle ◽  
Sam Sadigh ◽  
Jonathan Lake ◽  
Vania Aikawa ◽  
...  
Keyword(s):  
Acute Promyelocytic Leukemia ◽  
Promyelocytic Leukemia ◽  
Myeloid Neoplasm

scholarly journals Successful Treatment of a Case of Relapsed Acute Promyelocytic Leukemia with Arsenic Trioxide.

2001 ◽  
Vol 40 (11) ◽  
pp. 1136-1139
Author(s):  
Yasuo HIRAYAMA ◽  
Ryuzo KOYAMA ◽  
Tadanori NAGAI ◽  
Hidetoshi OHTA ◽  
Atsushi KONDO ◽  
...  
Keyword(s):  
Arsenic Trioxide ◽  
Acute Promyelocytic Leukemia ◽  
Successful Treatment ◽  
Promyelocytic Leukemia

Successful treatment of acute promyelocytic leukemia in pregnancy with single-agent all-trans retinoic acid

2017 ◽  
Vol 297 (2) ◽  
pp. 281-284 ◽  
Author(s):  
Cordula M. Nellessen ◽  
Viktor Janzen ◽  
Karin Mayer ◽  
Giulia Giovannini ◽  
Ulrich Gembruch ◽  
...  
Keyword(s):  
Retinoic Acid ◽  
Acute Promyelocytic Leukemia ◽  
Successful Treatment ◽  
Single Agent ◽  
Promyelocytic Leukemia ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid ◽  
In Pregnancy

scholarly journals Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial

2017 ◽  
Vol 35 (6) ◽  
pp. 605-612 ◽  
Author(s):  
Uwe Platzbecker ◽  
Giuseppe Avvisati ◽  
Laura Cicconi ◽  
Christian Thiede ◽  
Francesca Paoloni ◽  
...  
Keyword(s):  
Retinoic Acid ◽  
Arsenic Trioxide ◽  
Acute Promyelocytic Leukemia ◽  
Final Analysis ◽  
Promyelocytic Leukemia ◽  
Phase Iii ◽  
Intermediate Risk ◽  
Open Label ◽  
Myeloid Neoplasm ◽  
First Line Therapy

Purpose The initial results of the APL0406 trial showed that the combination of all- trans-retinoic acid (ATRA) and arsenic trioxide (ATO) is at least not inferior to standard ATRA and chemotherapy (CHT) in first-line therapy of low- or intermediate-risk acute promyelocytic leukemia (APL). We herein report the final analysis on the complete series of patients enrolled onto this trial. Patients and Methods The APL0406 study was a prospective, randomized, multicenter, open-label, phase III noninferiority trial. Eligible patients were adults between 18 and 71 years of age with newly diagnosed, low- or intermediate-risk APL (WBC at diagnosis ≤ 10 × 109/L). Overall, 276 patients were randomly assigned to receive ATRA-ATO or ATRA-CHT between October 2007 and January 2013. Results Of 263 patients evaluable for response to induction, 127 (100%) of 127 patients and 132 (97%) of 136 patients achieved complete remission (CR) in the ATRA-ATO and ATRA-CHT arms, respectively ( P = .12). After a median follow-up of 40.6 months, the event-free survival, cumulative incidence of relapse, and overall survival at 50 months for patients in the ATRA-ATO versus ATRA-CHT arms were 97.3% v 80%, 1.9% v 13.9%, and 99.2% v 92.6%, respectively ( P < .001, P = .0013, and P = .0073, respectively). Postinduction events included two relapses and one death in CR in the ATRA-ATO arm and two instances of molecular resistance after third consolidation, 15 relapses, and five deaths in CR in the ATRA-CHT arm. Two patients in the ATRA-CHT arm developed a therapy-related myeloid neoplasm. Conclusion These results show that the advantages of ATRA-ATO over ATRA-CHT increase over time and that there is significantly greater and more sustained antileukemic efficacy of ATO-ATRA compared with ATRA-CHT in low- and intermediate-risk APL.

Sign in / Sign up

Export Citation Format

Share Document